Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 5/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7589379 | 0.86 | L3MBTL1 (0.51) | L3MBTL1GPR119RIPK1NR1H2NR1H3 | |
| SCHEMBL27773399 | 0.85 | POLB (0.41) | POLB | |
| SCHEMBL3495689 | 0.79 | PDE4B (0.44) | DDB1CRBN | |
| SCHEMBL27528621 | 0.79 | RORC (0.46) | PRKCZL3MBTL1DDB1CRBNNR1H2 | |
| SCHEMBL29779454 | 0.79 | RORC (0.46) | PRKCZL3MBTL1DDB1CRBNNR1H2 | |
| SCHEMBL29779329 | 0.79 | RORC (0.46) | PRKCZL3MBTL1DDB1CRBNNR1H2 | |
| SCHEMBL22039428 | 0.79 | HTR7 (0.42) | PRKCZL3MBTL1DDB1CRBN | |
| SCHEMBL7236411 | 0.79 | HTR7 (0.42) | PRKCZL3MBTL1DDB1CRBN | |
| SCHEMBL23646533 | 0.77 | RIPK1 (0.50) | RIPK1NR1H2NR1H3 | |
| SCHEMBL21611363 | 0.77 | RIPK1 (0.50) | RIPK1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| CN-101415676-A | N-tert-butoxycarbonyl-2-pyrrolidinone compounds and method for producing the same | SUMITOMO CHEMICAL CO (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | ESR2 1362/4885KIF11 3487/4885PRKCZ 2618/4885 |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | TERT, CBR1, TELO2 | ESR2 1362/4885KIF11 3487/4885PRKCZ 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.